In October, Merck took up an option on the personalised RNA-based cancer vaccine with an upfront payment of $250 million as part of a collaboration first agreed in 2016 and expanded in 2018.

Proposed reforms to the regulations for pharmacy benefit managers (PBMs) were dropped from the US Congress' end-of-year bill to provide funding to the federal government. The eleventh-hour ...